블로그

혈우병

Why Is Hemophilia More Common in Males?

Hemophilia patient's hands holding red heart and blood drop

Hemophilia is more common in males due to the fact that they have only one copy of the gene on the X chromosome. If any changes occur in that gene, females can compensate for the defect with an additional copy of the gene, but males cannot. 

공제금 지원에 대해 전문가와 상담하세요

상담 일정을 잡으세요

It is also the reason why more males get other X-linked disorders like color blindness. X-linked disorders occur due to changes in the gene on the X chromosome.  

A Quick Overview of Hemophilia, Causes, Types, and Occurrence

Hemophilia is a genetic disorder in which the blood does not clot as it should. As a result, it can lead to excessive bruising and nosebleeds. Severe hemophilia can cause spontaneous bleeding (bleeding with no obvious cause). 
Hemophilia occurs due to changes in the genes that instruct the body to make blood-clotting proteins called clotting factors. The common types are:

  • Hemophilia A: Also known as classic hemophilia, it occurs due to having little or no clotting factor VIII. 
  • Hemophilia B: Also known as Christmas disease, it occurs due to having little or no clotting factor IX. 

The more common type—Hemophilia A—affects 1 in 5,000 male live births. According to reports from the 질병통제예방센터 (CDC), nearly 400 babies are born with this disorder each year in the U.S. Though the exact numbers remain unknown, recent data suggest about 33,000 American males have this condition [1].
 

Why Hemophilia Is More Common in Males: Understanding the Genetics and Inheritance

The fundamental reason why hemophilia is more common in males is that they have only one X chromosome. 

The X chromosome contains the genes for clotting factors VIII and IX. Changes in these genes lead to little or no clotting factor production. Consequently, the blood does not clot properly. 

The X chromosome contains the genes for clotting factors VIII and IX. Changes in these genes lead to little or no clotting factor production. Consequently, the blood does not clot properly. 

Because males have only one chromosome, one altered copy of the gene is enough to cause symptoms. On the other hand, females have two copies of these genes, and changes in one copy typically do not cause the condition. 

Moreover, males get an earlier diagnosis than females. Early diagnosis in males is a result of the myth that females cannot get hemophilia. Many females may even ignore the signs of mild hemophilia, such as heavy bleeding. 

According to a 2020 study, females with moderate symptoms receive a diagnosis about 6 months later than males. In severe cases, females face delays of approximately 40 months [2].

Hemophilia is more common in males born to a female carrying the affected gene and an unaffected male. In such cases, there is a 1 in 4 chance of having a baby boy with the condition. On the other hand, males born to a hemophilic father and unaffected mother are less likely to get the condition. 

The risk of hemophilia is the same for males and females if both parents have the faulty gene. In such cases, there is a 1 in 4 chance that a baby girl will be a carrier. 

재정 지원 받기

(877) 778-0318

Why Is Hemophilia Rare in Females?

For females to get hemophilia, both X chromosomes have to be altered. Sometimes, hemophilia may result from having one affected X chromosome and another non-functioning chromosome.  

A female with one altered gene is a “carrier.” She can pass the affected gene on to her children. Female carriers do not usually experience symptoms of hemophilia, but some do. 

The prevailing misbelief that hemophilia is a “male-only” disease could be one of the reasons for fewer diagnoses in females.

Key Takeaways

  • Hemophilia is more common in males because they have only one X chromosome. 
  • Though some providers consider it a “male-only” disease, hemophilia can affect females as well.  
  • Many health experts think underrecognition and underdiagnosis in females could obscure the real-world scenario. Females appear to get delayed diagnoses. 

참고문헌:

  1. “Data and Statistics | Hemophilia | NCBDDD | CDC.” Centers for Disease Control and Prevention, 1 Aug. 2022, www.cdc.gov/ncbddd/hemophilia/data.html.
  2. Weyand, Angela C, and Paula D James. “Sexism in the management of bleeding disorders.” Research and practice in thrombosis and haemostasis vol. 5,1 51-54. 13 Dec. 2020, doi:10.1002/rth2.12468
이 정보는 의학적 조언이나 치료를 대체할 수 없습니다. 새로운 치료를 시작하기 전에 담당 의사 또는 의료 서비스 제공자와 건강 상태에 대해 상담하십시오. AmeriPharma® Specialty Care는 제공된 정보 또는 그 결과로 내려진 진단이나 치료에 대해 어떠한 책임도 지지 않으며, 콘텐츠의 신뢰성에 대해서도 책임을 지지 않습니다. AmeriPharma® Specialty Care는 여기에 나열된 모든 웹사이트/기관을 운영하는 것은 아니며, 해당 콘텐츠의 가용성이나 신뢰성에 대해서도 책임을 지지 않습니다. 이러한 목록은 AmeriPharma® Specialty Care의 보증, 후원 또는 추천을 암시하거나 구성하지 않습니다. 이 웹페이지에는 AmeriPharma® Specialty Care와 제휴하지 않은 제약 회사의 상표 또는 등록 상표인 브랜드 처방약에 대한 참조가 포함될 수 있습니다.
의학적으로 검토됨 사바 라솔리 박사, 약학박사

사바 라술리 약학박사는 이란에서 태어나고 자랐습니다. 2022년 마셜 B. 케첨 대학교에서 우등(cum laude)으로 약학 학위를 받았습니다. 그녀의 일에서 가장 보람 있는 부분은 환자 한 분 한 분을 마치 가족처럼 돌보고, AmeriPharma에서 제공하는 서비스에 대한 환자들의 만족과 행복을 직접 듣는 것입니다. 여가 시간에는 산책을 즐기고, 책을 읽고, 다양한 레스토랑과 음식을 맛보는 것을 좋아합니다.

문의하기

아래 HIPAA 규격 양식을 사용하여 처방전 재조제를 요청하세요. 복용 중인 약이나 복용 방법에 대한 문의 사항이 있으시면 문의하기 페이지를 방문하시거나 다음 번호로 전화해 주세요. (877) 778-0318.

HIPAA Compliant

제출하면 AmeriPharma에 동의하는 것입니다. 이용 약관, 개인정보 보호정책, 그리고 개인정보 보호 관행 고지

ko_KRKorean